https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Oncol. Rep. 2005 Oct;14(4):969-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Oncol. Rep. 2005 Oct;14(4):969-732005-10-01 00:00:002019-02-15 09:03:11Administration of dendritic cells in cancer nodules in hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Zhonghua Xue Ye Xue Za Zhi 2005 Oct;26(10):593-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Zhonghua Xue Ye Xue Za Zhi 2005 Oct;26(10):593-72005-10-01 00:00:002019-02-15 08:51:02[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-212005-10-01 00:00:002019-02-15 09:25:41Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-28 / World J. Gastroenterol. 2005 Sep;11(36):5614-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-28 / World J. Gastroenterol. 2005 Sep;11(36):5614-202005-09-28 00:00:002019-02-15 09:03:09Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-292005-09-27 00:00:002005-09-27 00:00:00Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-26 / Clin. Immunol. 2006 Jan;118(1):66-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-26 / Clin. Immunol. 2006 Jan;118(1):66-762005-09-26 00:00:002019-02-15 09:25:38B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Nippon Rinsho 2005 Sep;63 Suppl 9:483-92005-09-01 00:00:002019-02-15 09:00:05[Current status of hyperthermia for therapy of brain tumor]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Hepatogastroenterology 2005 Sep-Oct;52(65):1502-62005-09-01 00:00:002019-02-15 09:03:11Immune-related effects of local hyperthermia in patients with primary liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-162005-09-01 00:00:002019-02-15 09:19:57Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-162005-09-01 00:00:002019-02-15 09:24:21[Vaccine therapy of prostate cancer]
